Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Reperfusion Injury
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Postoperative Complications » Reperfusion Injury
Description
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA. MeSH
Hierarchy View
Subtype Terms (3)
Myocardial Reperfusion Injury
27 drugs (21 approved, 6 experimental)
Post-Cardiac Arrest Syndrome
12 approved drugs
Primary Graft Dysfunction
3 drugs (2 approved, 1 experimental)
Phase 4 Indicated Drugs (20)
Phase 2 Indicated Drugs (22)
Phase 1 Indicated Drugs (5)
Other Experimental Indicated Drugs (23)
Organization Involved with Phase 4 Indications (42)
Organization Involved with Phase 3 Indications (25)
Organization Involved with Phase 2 Indications (41)
Istituto Clinico Humanitas - Rozzano (MI), Italy
Katholieke Universiteit Leuven
Nanyang Technological University
National Institute for Health Research, United Kingdom
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (21)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
